TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ALACRITA

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

ALACRITA

ST13

US500000085557129

Classe

35, 36, 42

Pedido

85557129

Registro

4256669

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

45

Atualização mais recente

01/07/2023

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

35, 36, 42

Data de depósito

01/03/2012

Data de registro

11/12/2012

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

30/06/2023

Última transação

30/06/2023

Escritório responsável

United States Patent and Trademark Office

Código da situação

800

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use

Código do desenho

4

Tipo de titular

03

Localização do titular

LONDON, GB

Examinador

SCHRODY, ALLISON PAIGE

Unidade examinadora

M60

Localização atual

GENERIC WEB UPDATE

Titulares e representantes

Titulares

ALACRITA HOLDINGS LIMITED
A. L. (pessoa física)

Representantes

Jeff Goehring Nixon & Vanderhye P.C.

Classificação técnica

Classes Nice

Classe 35Classe 36Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 35

Business and market research; business analysis, business planning, business management and business strategy, namely, strategic planning services, strategy development services and business consultancy in the fields of pharmaceuticals, biotechnology, life sciences, medical products, medical devices and healthcare industries; business advice regarding the development and commercialization of products in the fields of pharmaceuticals, biotechnology, life sciences, medical products, medical devices and healthcare industries; recruitment and personnel services, namely, personnel placement; tax services, namely, tax consultation and accountancy services; advertising and promotional services; arranging business networking meeting opportunities for businesses to meet potential investors and to promote their products; information, consultancy and advice relating to any of the aforesaid services; management of clinical trials for drugs, vaccines, diagnostic reagents, small molecules, medical devices, namely, providing information management services, providing clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and application for drug approval, or providing independent reviews of clinical trials for business purposes; preparation of reports on clinical trials of drugs, vaccines, diagnostic reagents, small molecules, and medical devices, namely, providing information, management and compilation of computerized databases in the field of clinical trials for business purposes; preparing technical business or financial reports on clinical trials of drugs, vaccines, diagnostic reagents, small molecules, medical devices, preparation of reports on clinical trials of drugs, vaccines, diagnostic reagents, small molecules, and medical devices

Classe 36

Financial advice for companies in the fields of pharmaceuticals, biotechnology, life sciences, medical products, medical devices and healthcare industries; arranging funding, namely, providing financing services, investment consultancy; information, consultancy and advice relating to any of the aforesaid services

Classe 42

Research in the field of pharmaceuticals, biotechnology, life sciences, medical products, medical devices and scientific research in the field of healthcare industries; clinical research, namely, managing clinical trials for others, providing medical and scientific research information in the field of clinical trials; testing of pharmaceuticals, diagnostic reagents or medical products; conducting of clinical trials for others for drugs, vaccines, diagnostic reagents, small molecules, medical devices; providing scientific information, namely, preparation of reports on clinical trials of drugs, vaccines, diagnostics, small molecules, cellular therapies, medical devices, and research reagents; scientific research, namely, writing of medical research and scientific research-related documents and preparing reports on medical research and scientific research-related documents; testing the safety of pharmaceuticals, vaccines, diagnostic reagents, small molecules, cellular therapies, and medical devices, and information, consultancy and advice relating to any of the aforesaid services; consultancy, advice and information in the field of development of drugs, vaccines, diagnostic reagents, small molecules, and medical devices

Publicações

Histórico de despachos e eventos da marca no USPTO.

45 publicações encontradas

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

01/07/2023

RNL1

REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)

30/06/2023

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

30/06/2023

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

30/06/2023

E89R

TEAS SECTION 8 & 9 RECEIVED

06/12/2022

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

11/12/2021

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

15/11/2020

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

15/11/2020

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

15/11/2020

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

15/11/2020

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

15/11/2020

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

15/11/2020

NAS8

NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED

08/12/2018

8.OK

REGISTERED - SEC. 8 (6-YR) ACCEPTED

08/12/2018

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

08/12/2018

ES8R

TEAS SECTION 8 RECEIVED

03/12/2018

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

11/12/2017

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

24/05/2017

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

19/03/2014

R.PR

REGISTERED-PRINCIPAL REGISTER

11/12/2012

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

25/09/2012

PUBO

PUBLISHED FOR OPPOSITION

25/09/2012

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

05/09/2012

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

22/08/2012

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

22/08/2012

XAEC

EXAMINER'S AMENDMENT ENTERED

22/08/2012

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

22/08/2012

GNEA

EXAMINERS AMENDMENT E-MAILED

22/08/2012

CNEA

EXAMINERS AMENDMENT -WRITTEN

22/08/2012

ACEC

AMENDMENT FROM APPLICANT ENTERED

16/08/2012

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

16/08/2012

FAXX

FAX RECEIVED

14/08/2012

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

31/07/2012

GNFR

FINAL REFUSAL E-MAILED

31/07/2012

CNFR

FINAL REFUSAL WRITTEN

31/07/2012

ACEC

AMENDMENT FROM APPLICANT ENTERED

12/07/2012

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/07/2012

ALIE

ASSIGNED TO LIE

12/07/2012

FAXX

FAX RECEIVED

02/07/2012

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

19/06/2012

GNRT

NON-FINAL ACTION E-MAILED

19/06/2012

CNRT

NON-FINAL ACTION WRITTEN

19/06/2012

DOCK

ASSIGNED TO EXAMINER

12/06/2012

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/03/2012

NWAP

NEW APPLICATION ENTERED

05/03/2012

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ALACRITA ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.